Table 2.
Univariate Cox regression for progression of BOS stage 1 to death
| Variable | Death |
|
|---|---|---|
| Hazard Ratio (95% CI) | p | |
| Time Dependent | ||
| No Azithromycin | 1.00 | |
| Azithromycin (total group) | 1.08 (0.66–1.74) | 0.78 |
| Azithromycin during BOS 1 | 0.29 (0.11–0.82) | 0.02 |
| Azithromycin Post-BOS 2 | 1.54 (0.91–2.61) | 0.11 |
| Time Independent* | ||
| Female | 1.28 (0.79–2.10) | 0.32 |
| Age at transplant (per year) | 1.00 (0.98–1.02) | 0.65 |
| Underlying Disease | 0.51 | |
| COPD | 1.00 | |
| α1-AT | 1.65 (0.82–3.35) | |
| Cystic Fibrosis | 1.56 (0.77–3.14) | |
| Pulmonary Fibrosis | 1.11 (0.43–2.84) | |
| Other | 0.76 (0.18–3.15) | |
| Ischemic Time (per min) | 1.00 (1.00–1.01) | 0.26 |
| Ischemic Time > 330 min | 1.41 (0.86–2.30) | 0.17 |
| Date of transplant, (per day) | 1.00 (1.00-1.00) | 0.64 |
| Type of Transplant | 0.87 | |
| Bilateral | 1.00 | |
| Single | 1.09 (0.40–3.01) | |
| PGD at T0 | 0.052 | |
| 0 | 1.00 | |
| 1 | 1.74 (0.71–4.21) | |
| 2 | 1.95 (0.78–4.93) | |
| 3 | 3.57 (1.35–9.41) | |
| Highest A score | 0.74 | |
| 0 | 1.00 | |
| 1 | 1.48 (0.71–3.08) | |
| 2 | 1.14 (0.58–2.26) | |
| 3 | 1.23 (0.48–3.14) | |
| Highest B score | 0.99 | |
| 0 | 1.00 | |
| 1 | 1.03 (0.58–1.86) | |
| 2 | 1.09 (0.54–2.20) | |
| 3 | 1.17 (0.27–5.09) | |
| Pseudomonas culture positive | 1.74 (1.04–2.93) | 0.04 |
| CMV pneumonia | 1.03 (0.63–1.68) | 0.92 |
| CARV infection | 1.10 (0.60–2.03) | 0.76 |
| FEV1 at BOS stage 1 (per liter) | 0.47 (0.33–0.66) | <0.001 |
| Antithymocyte globulin for BOS stage 1 | 0.82 (0.49–1.38) | 0.46 |
*
Time independent analysis included No Azithro (n=95) and Early Azithro (n=31) cohorts
Definition of abbreviations: see Table 1